Time of interferon-β 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients

Abstract

During initiation of interferon-beta (IFN-β) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-β injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-β either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-β therapy.

Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-β administration. IFN-β injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-β injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-β treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-β therapy only in group A.

Our results show that time point of IFN-β injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-β therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.com

Keywords

time point of injection interferon-β cytokine hormones side effects multiple sclerosis

Get full access to this article

View all access options for this article.

References

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 52: 1498—504.

The IFNβ Multiple sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655—61.

Neilley LK , Goodin DS , Goodkin DE , Hauser SL Side effect profile of interferon beta-1b in multiple sclerosis: results of an open label trial. Neurology 1996; 46: 552—54.

Goebel MU , Baase J. , Pithan V. , Exto MS , Saller B. , Schedlowski M. et al. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects . Psychoneuroendocrinology 2002; 27: 881—92.

Kümpfel T. , Then Bergh F , Pollmächer T. , Holsboer F. , Trenkwalder C. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000; 55: 1231—33.

Ohno Y. , Fujimoto M. , Nishimura A. , Aoki N.

Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)- β in patients with chronic hepatitis

C. J Clin Endocrinol Metabol 1998; 83: 3681—87.

Petrovsky N. , McNair P. , Harrison LC Diurnal rhythms of proinflammatory cytokines: Regulation by plasma cortisol and therapeutic implications. Cytokine 1998; 10: 307—12.

Mormont MC , Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155—69.

Ozaydin M. , Dede O. , Dogan A. , Aslan MS , Altinbas A. , Ozturk M. et al. Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis in patients undergoing first elecvtive percutaneous coronary intervention. Am J Cardiol 2006; 97: 44—47.

10.

Cutolo M. , Sulli A. , Pizzorni C. , Secchi ME , Soldano S. , Seriolo B. et al. Circadian rhytms: glucocorticoids and arthritis. Ann N Y Acad Sci 2006; 1069: 289—99.

11.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—27.

12.

Montalban X. , Duran I. , Rio J. , Saez-Torres I. , Tintore M. , Martinez- Caceres EM Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta ? J Neurol 2000; 247: 259—62.

13.

Nicoletti F. , Marco R. , Patti F. , Zaccone P. , L'Episcopo MR , Reggio E. et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-γ without significantly modifying those of IL-1β, IL-2, IL-4 and tumor necrosis factor-α. Cytokine 2000; 12: 682—87.

14.

Evans A. , Main E. , Zier K. , Ikegaki N. , Tartaglione Mkennett R , Lampson L. The effects of gamma interferon on natural killer and tumor cells of children with neuroblastoma. A preleminary report. Cancer 1989; 64: 1383—87.

15.

Pollmächer T. , Mullington J. , Korth C. , Schrieber W. , Hermann D. , Orth A. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis 1996; 174: 1040—45.

16.

Martinez-Caceres EM , Rio J. , Barrau M. , Duran BS , Borras BS , Tintore M. et al. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol 1998; 4: 682—85.

17.

Young MR , Metthews JP , Kanabrocki EL , Sothern RB , Roitman-Johnson B. , Scheving LE Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor alpha and granulocyte.macrophage colony-stimulating factor in men. Chronobiol Int 1995; 12: 19—27.

18.

Petrovsky N. Towards a unified model of neuroendocrineimmune interaction. Immunol and Cell Biol 2001; 79: 350—57.

19.

Ersoy E. , Kus C. , Sener U. , Çoker I. , Zorlu, Y. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients . Eur J Neurol 2005; 12: 208—11.

20.

Rep MH , Schrijver HM , van Lopik T. , Hintzen RQ , Roos MT , Ader HJ et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999; 96: 92—100.

21.

Laske C. , Oschmann P. , Tofighi J. , Kuehne SB , Diehl H. , Bregenzer T. et al. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol Scand 2001; 103: 105—13.

22.

Rieckmann P. , Kruse N. , Nagelkerken L. , Beckmann K. , Miller D. , Polmann C. et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. J Neurol 2005; 252: 526—33.

23.

The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457—65.

24.

Mormont MC , Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155—69.

25.

Ohdo S. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety. Drug Saf 2003 ; 26: 999—1010.